glp-1 agonist benefits EASD 2018: of GIP/GLP-1 receptor co-agonists in T2D GLP 1s for Weight Loss

Tirzepatide once Weekly for the treatment of obesity

ER stress and the unfolded protein response in neurodegeneration

doi: 10.1016/S0140-6736(64)90011-X [DOI] [PubMed] [Google Scholar] 6

Hybrid care models integrating pharmacotherapy with lifestyle support show promise for sustainable outcomes ( 3.2 Divergent muscle outcomes in weight loss interventions

Market Statistics Key Takeaways By type of GLP-1 agonist drugs, the long-acting GLP-1 agonist segment dominated in 2025

examined 19 clinical trials that investigated the use of exenatide, semaglutide, and liraglutide as pharmacologic options for treating childhood obesity alongside behavioral and lifestyle interventions, as well as surgical approaches